Gel electrophoresis is a critical technique in recombinant DNA technology used for the separation and analysis of DNA fragments. In the context of rDNA, it is employed to verify the size and purity of extracted DNA or to confirm the successful incorporation of the target gene into the vector. The process involves applying an electric current to a gel containing DNA samples, causing the DNA fragments to migrate through the gel at rates depending on their size. Smaller fragments move faster and farther than larger ones. By comparing the migration of these fragments to a known size standard, scientists can determine the size of the DNA pieces, crucial for verifying the success of cloning procedures and ensuring the integrity of the recombinant DNA.

Bacteria, especially E. coli, are commonly used as host cells in recombinant DNA technology due to several advantageous properties. They have a rapid growth rate, allowing for the quick production of large quantities of the desired product. Bacteria also have relatively simple genetics, which makes them easier to manipulate compared to more complex eukaryotic cells. Their ability to take up foreign DNA (competence) and the availability of well-understood plasmid vectors further facilitate their use in rDNA technology. Additionally, bacteria do not have the ethical and regulatory concerns associated with using animal or human cells, making them a practical choice for many applications in genetic engineering.

Reverse transcriptase is an enzyme that plays a vital role in recombinant DNA technology, particularly in the study and manipulation of genes expressed in eukaryotic cells. This enzyme converts RNA into complementary DNA (cDNA), a process known as reverse transcription. It is especially important when the gene of interest is only available in the form of mRNA, such as in the case of eukaryotic genes that have undergone post-transcriptional modifications like splicing. By converting mRNA back into DNA, reverse transcriptase allows for the cloning and further study of these specific genes. cDNA, being free of introns, is particularly useful for expressing eukaryotic genes in bacterial systems, as bacteria lack the machinery to remove introns.

Safety concerns associated with recombinant DNA technology are primarily related to the potential for unintended environmental impact and issues of bioethics. For instance, the release of genetically modified organisms (GMOs) into the environment may have unpredictable effects on ecosystems, including crossbreeding with wild species or affecting biodiversity. Additionally, there are concerns about antibiotic resistance markers used in some rDNA techniques, as these could contribute to the growing issue of antibiotic resistance if transferred to other organisms. Ethical concerns also arise, particularly in the context of genetic modifications in humans or animals, raising questions about the long-term impacts and moral implications of altering genetic material.

Recombinant DNA technology has revolutionised the production of human insulin, making it more accessible and safe for diabetic patients. Previously, insulin was extracted from animal pancreases, but this method posed risks of allergic reactions and was insufficient to meet global demand. Using rDNA technology, the gene responsible for insulin production in humans is inserted into a plasmid vector and then introduced into bacteria like E. coli. These bacteria then act as biological factories, producing human insulin as they grow and multiply. This insulin is then harvested, purified, and formulated for medical use, ensuring a reliable and identical match to human insulin, reducing the risk of adverse reactions.